American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors

Timothy D. Gilligan, Jerome Seidenfeld, Ethan M. Basch, Lawrence H. Einhorn, Timothy Fancher, David C. Smith, Andrew J. Stephenson, David J. Vaughn, Roxanne Cosby, Daniel F. Hayes

Research output: Contribution to journalReview article

131 Citations (Scopus)

Abstract

Purpose: To provide recommendations on appropriate uses for serum markers of germ cell tumors (GCTs). Methods: Searches of MEDLINE and EMBASE identified relevant studies published in English. Primary outcomes included marker accuracy to predict the impact of decisions on outcomes. Secondary outcomes included proportions of patients with elevated markers and statistical tests of elevations as prognostic factors. An expert panel developed consensus guidelines based on data from 82 reports. Results: No studies directly compared outcomes of decisions with versus without marker assays. The search identified few prospective studies and no randomized controlled trials; most were retrospective series. Lacking data on primary outcomes, most Panel recommendations are based on secondary outcomes (relapse rates and time to relapse). Recommendations: The Panel recommended against using markers to screen for GCTs, to decide whether orchiectomy is indicated, or to select treatment for patients with cancer of unknown primary. To stage patients with testicular nonseminomas, the Panel recommended measuring three markers (α-fetoprotein [AFP], human chorionic gonadotropin [hCG], and lactate dehydrogenase [LDH]) before and after orchiectomy and before chemotherapy for those with extragonadal nonseminomas. They also recommended measuring AFP and hCG shortly before retroperitoneal lymph node dissection and at the start of each chemotherapy cycle for nonseminoma, and periodically to monitor for relapse. The Panel recommended measuring postorchiectomy hCG and LDH for patients with seminoma and preorchiectomy elevations. They recommended against using markers to guide or monitor treatment for seminoma or to detect relapse in those treated for stage I. However, they recommended measuring hCG and AFP to monitor for relapse in patients treated for advanced seminoma.

Original languageEnglish (US)
Pages (from-to)3388-3404
Number of pages17
JournalJournal of Clinical Oncology
Volume28
Issue number20
DOIs
StatePublished - Jul 10 2010

Fingerprint

Medical Oncology
Tumor Biomarkers
Practice Guidelines
Chorionic Gonadotropin
Biomarkers
Seminoma
Recurrence
Orchiectomy
Germ Cell and Embryonal Neoplasms
L-Lactate Dehydrogenase
Fetal Proteins
Drug Therapy
Lymph Node Excision
MEDLINE
Randomized Controlled Trials
Male Germ Cell Tumor
Prospective Studies
Guidelines
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. / Gilligan, Timothy D.; Seidenfeld, Jerome; Basch, Ethan M.; Einhorn, Lawrence H.; Fancher, Timothy; Smith, David C.; Stephenson, Andrew J.; Vaughn, David J.; Cosby, Roxanne; Hayes, Daniel F.

In: Journal of Clinical Oncology, Vol. 28, No. 20, 10.07.2010, p. 3388-3404.

Research output: Contribution to journalReview article

Gilligan, TD, Seidenfeld, J, Basch, EM, Einhorn, LH, Fancher, T, Smith, DC, Stephenson, AJ, Vaughn, DJ, Cosby, R & Hayes, DF 2010, 'American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors', Journal of Clinical Oncology, vol. 28, no. 20, pp. 3388-3404. https://doi.org/10.1200/JCO.2009.26.4481
Gilligan, Timothy D. ; Seidenfeld, Jerome ; Basch, Ethan M. ; Einhorn, Lawrence H. ; Fancher, Timothy ; Smith, David C. ; Stephenson, Andrew J. ; Vaughn, David J. ; Cosby, Roxanne ; Hayes, Daniel F. / American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors. In: Journal of Clinical Oncology. 2010 ; Vol. 28, No. 20. pp. 3388-3404.
@article{669d77cf8c784c58a8e8f1556f55ed50,
title = "American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors",
abstract = "Purpose: To provide recommendations on appropriate uses for serum markers of germ cell tumors (GCTs). Methods: Searches of MEDLINE and EMBASE identified relevant studies published in English. Primary outcomes included marker accuracy to predict the impact of decisions on outcomes. Secondary outcomes included proportions of patients with elevated markers and statistical tests of elevations as prognostic factors. An expert panel developed consensus guidelines based on data from 82 reports. Results: No studies directly compared outcomes of decisions with versus without marker assays. The search identified few prospective studies and no randomized controlled trials; most were retrospective series. Lacking data on primary outcomes, most Panel recommendations are based on secondary outcomes (relapse rates and time to relapse). Recommendations: The Panel recommended against using markers to screen for GCTs, to decide whether orchiectomy is indicated, or to select treatment for patients with cancer of unknown primary. To stage patients with testicular nonseminomas, the Panel recommended measuring three markers (α-fetoprotein [AFP], human chorionic gonadotropin [hCG], and lactate dehydrogenase [LDH]) before and after orchiectomy and before chemotherapy for those with extragonadal nonseminomas. They also recommended measuring AFP and hCG shortly before retroperitoneal lymph node dissection and at the start of each chemotherapy cycle for nonseminoma, and periodically to monitor for relapse. The Panel recommended measuring postorchiectomy hCG and LDH for patients with seminoma and preorchiectomy elevations. They recommended against using markers to guide or monitor treatment for seminoma or to detect relapse in those treated for stage I. However, they recommended measuring hCG and AFP to monitor for relapse in patients treated for advanced seminoma.",
author = "Gilligan, {Timothy D.} and Jerome Seidenfeld and Basch, {Ethan M.} and Einhorn, {Lawrence H.} and Timothy Fancher and Smith, {David C.} and Stephenson, {Andrew J.} and Vaughn, {David J.} and Roxanne Cosby and Hayes, {Daniel F.}",
year = "2010",
month = "7",
day = "10",
doi = "10.1200/JCO.2009.26.4481",
language = "English (US)",
volume = "28",
pages = "3388--3404",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "20",

}

TY - JOUR

T1 - American society of clinical oncology clinical practice guideline on uses of serum tumor markers in adult males with germ cell tumors

AU - Gilligan, Timothy D.

AU - Seidenfeld, Jerome

AU - Basch, Ethan M.

AU - Einhorn, Lawrence H.

AU - Fancher, Timothy

AU - Smith, David C.

AU - Stephenson, Andrew J.

AU - Vaughn, David J.

AU - Cosby, Roxanne

AU - Hayes, Daniel F.

PY - 2010/7/10

Y1 - 2010/7/10

N2 - Purpose: To provide recommendations on appropriate uses for serum markers of germ cell tumors (GCTs). Methods: Searches of MEDLINE and EMBASE identified relevant studies published in English. Primary outcomes included marker accuracy to predict the impact of decisions on outcomes. Secondary outcomes included proportions of patients with elevated markers and statistical tests of elevations as prognostic factors. An expert panel developed consensus guidelines based on data from 82 reports. Results: No studies directly compared outcomes of decisions with versus without marker assays. The search identified few prospective studies and no randomized controlled trials; most were retrospective series. Lacking data on primary outcomes, most Panel recommendations are based on secondary outcomes (relapse rates and time to relapse). Recommendations: The Panel recommended against using markers to screen for GCTs, to decide whether orchiectomy is indicated, or to select treatment for patients with cancer of unknown primary. To stage patients with testicular nonseminomas, the Panel recommended measuring three markers (α-fetoprotein [AFP], human chorionic gonadotropin [hCG], and lactate dehydrogenase [LDH]) before and after orchiectomy and before chemotherapy for those with extragonadal nonseminomas. They also recommended measuring AFP and hCG shortly before retroperitoneal lymph node dissection and at the start of each chemotherapy cycle for nonseminoma, and periodically to monitor for relapse. The Panel recommended measuring postorchiectomy hCG and LDH for patients with seminoma and preorchiectomy elevations. They recommended against using markers to guide or monitor treatment for seminoma or to detect relapse in those treated for stage I. However, they recommended measuring hCG and AFP to monitor for relapse in patients treated for advanced seminoma.

AB - Purpose: To provide recommendations on appropriate uses for serum markers of germ cell tumors (GCTs). Methods: Searches of MEDLINE and EMBASE identified relevant studies published in English. Primary outcomes included marker accuracy to predict the impact of decisions on outcomes. Secondary outcomes included proportions of patients with elevated markers and statistical tests of elevations as prognostic factors. An expert panel developed consensus guidelines based on data from 82 reports. Results: No studies directly compared outcomes of decisions with versus without marker assays. The search identified few prospective studies and no randomized controlled trials; most were retrospective series. Lacking data on primary outcomes, most Panel recommendations are based on secondary outcomes (relapse rates and time to relapse). Recommendations: The Panel recommended against using markers to screen for GCTs, to decide whether orchiectomy is indicated, or to select treatment for patients with cancer of unknown primary. To stage patients with testicular nonseminomas, the Panel recommended measuring three markers (α-fetoprotein [AFP], human chorionic gonadotropin [hCG], and lactate dehydrogenase [LDH]) before and after orchiectomy and before chemotherapy for those with extragonadal nonseminomas. They also recommended measuring AFP and hCG shortly before retroperitoneal lymph node dissection and at the start of each chemotherapy cycle for nonseminoma, and periodically to monitor for relapse. The Panel recommended measuring postorchiectomy hCG and LDH for patients with seminoma and preorchiectomy elevations. They recommended against using markers to guide or monitor treatment for seminoma or to detect relapse in those treated for stage I. However, they recommended measuring hCG and AFP to monitor for relapse in patients treated for advanced seminoma.

UR - http://www.scopus.com/inward/record.url?scp=77954695955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954695955&partnerID=8YFLogxK

U2 - 10.1200/JCO.2009.26.4481

DO - 10.1200/JCO.2009.26.4481

M3 - Review article

C2 - 20530278

AN - SCOPUS:77954695955

VL - 28

SP - 3388

EP - 3404

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 20

ER -